Compare
AN2 Therapeutics, Inc. vs Lifevantage Corp vs OnKure Therapeutics, Inc. vs Q32 Bio Inc.
| Latest fiscal year | AN2 Therapeutics, Inc. ANTX | Lifevantage Corp LFVN | OnKure Therapeutics, Inc. OKUR | Q32 Bio Inc. QTTB |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2026-06-30 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $182.59M | n/a | $53.74M |
| Revenue growth (YoY) | n/a | -20.1% | n/a | n/a |
| Gross margin | n/a | 77.6% | n/a | n/a |
| Operating margin | n/a | 3.3% | n/a | 31.5% |
| Net margin | n/a | 2.8% | n/a | 55.5% |
| Net income | -$35.17M | $5.07M | -$59.52M | $29.82M |
| EPS (Diluted) | -$1.16 | $0.40 | -$4.40 | $2.42 |
| Operating cash flow | -$29.83M | $10.24M | -$51.83M | -$33.54M |
| Free cash flow | n/a | $6.67M | -$51.87M | -$33.54M |
| Cash & equivalents | $19.94M | n/a | $59.05M | $48.30M |
| Total assets | $61.95M | $62.11M | $62.12M | $61.78M |
| Total liabilities | $8.89M | $28.52M | $5.93M | $19.76M |
| Shareholders' equity | $53.06M | $33.59M | $56.18M | $42.01M |
| Return on year-end equity | -66.3% | 15.1% | -105.9% | 71.0% |
| Shares outstanding | 27.41M | 12.52M | n/a | 12.86M |
Revenue, most recent five fiscal years
| Fiscal year | AN2 Therapeutics, Inc. | Lifevantage Corp | OnKure Therapeutics, Inc. | Q32 Bio Inc. |
|---|---|---|---|---|
| Latest | n/a | $182.59M Ended 2026-06-30 | $0 Ended 2024-12-31 | $53.74M Ended 2025-12-31 |
| 1 year earlier | n/a | $228.53M Ended 2025-06-30 | n/a | $0 Ended 2024-12-31 |
| 2 years earlier | n/a | $200.16M Ended 2024-06-30 | n/a | -$6.65M Ended 2023-12-31 |
| 3 years earlier | n/a | $213.40M Ended 2023-06-30 | n/a | n/a |
| 4 years earlier | n/a | $206.36M Ended 2022-06-30 | n/a | n/a |